Details

Autor(en) / Beteiligte

• Van Tassell, Benjamin W
• Abouzaki, Nayef A
• Oddi Erdle, Claudia
• Carbone, Salvatore
• Trankle, Cory R
• Melchior, Ryan D
• Turlington, Jeremy S
• Thurber, Clinton J
• Christopher, Sanah
• Dixon, Dave L
• Fronk, Daniel T
• Thomas, Christopher S
• Rose, Scott W
• Buckley, Leo F
• Dinarello, Charles A
• Biondi-Zoccai, Giuseppe
• Abbate, Antonio

Titel

Interleukin-1 Blockade in Acute Decompensated Heart Failure: A Randomized, Double-Blinded, Placebo-Controlled Pilot Study

Ist Teil von

• Journal of cardiovascular pharmacology, 2016-06, Vol.67 (6), p.544-551

Ort / Verlag

United States: Copyright Wolters Kluwer Health, Inc. All rights reserved

Erscheinungsjahr

2016

Quelle

MEDLINE

Beschreibungen/Notizen

• BACKGROUND:Heart failure is an inflammatory disease. Patients with acute decompensated heart failure (ADHF) exhibit significant inflammatory activity on admission. We hypothesized that Interleukin-1 blockade, with anakinra (Kineret, Swedish Orphan Biovitrum), would quench the acute inflammatory response in patients with ADHF. METHODS:We randomized 30 patients with ADHF, reduced left ventricular ejection fraction (<40%), and elevated C reactive protein (CRP) levels (≥5 mg/L) to either anakinra 100 mg twice daily for 3 days followed by once daily for 11 days or matching placebo, in a 1:1 double blinded fashion. We measured daily CRP plasma levels using a high-sensitivity assay during hospitalization and then again at 14 days and evaluated the area-under-the-curve and interval changes (delta). RESULTS:Treatment with anakinra was well tolerated. At 72 hours, anakinra reduced CRP by 61% versus baseline, compared with a 6% reduction among patients receiving placebo (P = 0.004 anakinra vs. placebo). CONCLUSIONS:Interleukin-1 blockade with anakinra reduces the systemic inflammatory response in patients with ADHF. Further studies are warranted to determine whether this anti-inflammatory effect translates into improved clinical outcomes.